Patents Examined by Erich A. Leeser
-
Patent number: 12291538Abstract: The disclosure provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein W1, W2, Y, Z, M, L, Cy, Cz, R1, R2, R3, R4, R2a, Ry, Rz, and the subscripts m, n, q, and r are as described herein. The compounds or their pharmaceutically acceptable salts can inhibit the G12C mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.Type: GrantFiled: May 3, 2023Date of Patent: May 6, 2025Assignee: Merck Sharp & Dohme LLCInventors: Indu Bharathan, Symon Gathiaka, Yongxin Han, Xiaoshen Ma, Ryan D. Otte, David L. Sloman, Thomas H. Graham, Timothy Henderson, Elisabeth Hennessy, Anandan Palani
-
Patent number: 12286411Abstract: The invention relates to an indane compound according to Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, L, n and p are as defined herein. The compounds are useful for treating antibacterial infection either as stand-alone antibiotics, or in combination with further antibiotics.Type: GrantFiled: July 25, 2019Date of Patent: April 29, 2025Assignee: Antabio SASInventors: Simon Leiris, David Thomas Davies, Martin Everett, Nicolas Sprynski, Lilha Beyria, Thomas David Pallin, Andrew Peter Cridland, Toby Jonathan Blench, Richard Leonard Elliott, David Edward Clark
-
Patent number: 12263190Abstract: The present disclosure relates in some aspects to methods, compositions and uses involving immunotherapies, such as adoptive cell therapy, e.g., T cell therapy, and an immunomodulatory compound, such as a structural or functional analog or derivative of thalidomide and/or an inhibitor of E3-ubiquitin ligase. The provided methods, compositions and uses include those for combination therapies involving the administration or use of one or more immunomodulatory compounds in conjunction with a T cell therapy, such as a genetically engineered T cell therapy involving cells engineered with a recombinant receptor, such as chimeric antigen receptor (CAR)-expressing T cells. Also provided are compositions, methods of administration to subjects, articles of manufacture and kits for use in the methods.Type: GrantFiled: November 7, 2019Date of Patent: April 1, 2025Assignee: Juno Therapeutics, Inc.Inventors: Jens Hasskarl, Stanley R. Frankel, Michael Ports, Michael Pourdehnad, Heidi Jessup, Yue Jiang, Jim Shi Xiang Qin, Neha Soni, Melissa Works
-
Patent number: 12257215Abstract: The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC0-tau less than 400 ng·h/mL, (ii) a Cmax no more than 40 ng/mL, or (iii) both.Type: GrantFiled: May 24, 2024Date of Patent: March 25, 2025Assignee: SPRINGWORKS THERAPEUTICS, INC.Inventors: Uchenna H. Iloeje, Abraham J. Langseth, Todd Webster Shearer
-
Patent number: 12247010Abstract: Provided herein are compounds, pharmaceutical compositions, and methods of treatment for various diseases, such as cancer. In one aspect, the method comprises the treatment of brain cancers or metastatic cancers that spread to the brain.Type: GrantFiled: April 29, 2021Date of Patent: March 11, 2025Inventors: Tom Lin, Cheng-Chi Irene Wang, Jason Olejniczak, Jessica Crisp, Richard Truong
-
Patent number: 12240851Abstract: Novel pyrido[3?,4?:4,5]pyrrolo[3,2-c]naphthyridine compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The pyrido[3?,4?:4,5]pyrrolo[3,2-c]naphthyridine compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.Type: GrantFiled: December 5, 2023Date of Patent: March 4, 2025Assignee: KING FAISAL UNIVERSITYInventors: Christophe Tratrat, Michelyne Haroun
-
Patent number: 12240833Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.Type: GrantFiled: May 27, 2022Date of Patent: March 4, 2025Assignee: EDGEWISE THERAPEUTICS, INC.Inventors: Kevin Hunt, Kevin Koch, Alan Russell, Stephen Schlachter, Paul Winship, Grace Uzoho, Chris Steele
-
Patent number: 12234230Abstract: Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.Type: GrantFiled: June 29, 2022Date of Patent: February 25, 2025Assignee: NURIX THERAPEUTICS, INC.Inventors: Arthur T. Sands, Neil F. Bence, Christoph W. Zapf, Frederick Cohen, Chenbo Wang, Thomas Cummins, Hiroko Tanaka, Hunter Shunatona, Mario Cardozo, Dahlia Weiss, Jennifa Gosling
-
Patent number: 12220390Abstract: The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC0-tau less than 400 ng·h/mL, (ii) a Cmax no more than 40 ng/mL, or (iii) both.Type: GrantFiled: May 24, 2024Date of Patent: February 11, 2025Assignee: SPRINGWORKS THERAPEUTICS, INC.Inventors: Uchenna H. Iloeje, Abraham J. Langseth, Todd Webster Shearer
-
Patent number: 12221449Abstract: Provided is a new compound capable of effectively inhibiting ATX. The compound is represented by formula I, or the compound is a tautomer, a stereoisomer, a hydrate, a solvate, a salt, or a prodrug of the compound represented by formula I. In formula (I), R1 and R2 are independently selected from —H or —CH3, provided that: R1 and R2 are not —H at the same time or are not —CH3 at the same time.Type: GrantFiled: January 22, 2020Date of Patent: February 11, 2025Assignee: WUHAN HUMANWELL INNOVATIVE DRUG RESEARCH AND DEVELOPMENT CENTER LIMITED COMPANYInventors: Xuejun Zhang, Dabing Ye, Lie Li, Jie Shen, Xiaohua Ding, Hongna Sun, Zhe Liu, Yang Zang, Yonggang Wei
-
Patent number: 12215086Abstract: This invention is directed to pyrrole, pyrazole, imidazole, triazole, and morpholine based selective androgen receptor degrader (SARD) compounds including heterocyclic anilide rings and their synthetic precursors. R-isomers, and non-hydroxylated and/or non-chiral propenamides, and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic to or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.Type: GrantFiled: January 24, 2022Date of Patent: February 4, 2025Assignee: University of Tennessee Research FoundationInventors: Ramesh Narayanan, Duane D. Miller, Thamarai Ponnusamy, Dong-Jin Hwang, Yali He
-
Patent number: 12213957Abstract: The present invention relates to the use of aminoacetonitrile derivatives (AADs) in the treatment of cancer and mTOR (mammalian Target of Rapamycin) pathway related diseases. In particular it relates to the use of AADs administered at particular dose amounts in order to achieve therapeutic effects.Type: GrantFiled: May 11, 2021Date of Patent: February 4, 2025Assignee: PITNEY PHARMACEUTICALS PTY LIMITEDInventors: Roger Aston, Richard Mollard
-
Patent number: 12180217Abstract: Compounds and methods of using said compounds, singly or in combination with additional agents, and salts or pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.Type: GrantFiled: March 11, 2024Date of Patent: December 31, 2024Assignee: Gilead Sciences, Inc.Inventors: Mark J. Bartlett, Daniel H. Byun, Yifan Deng, Jennifer L. Cosman Ellis, Rao V. Kalla, Richard L Mackman, Dustin S. Siegel, Xianhuang Zeng
-
Patent number: 12171756Abstract: The present invention provides compounds of Formula (I): wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).Type: GrantFiled: April 28, 2022Date of Patent: December 24, 2024Assignee: INNATE TUMOR IMMUNITY, INC.Inventors: Daniel O'Malley, Ashvinikumar V. Gavai, Patrice Gill, Christine M. Tarby, Scott Hunter Watterson, Hua Gong, David K. Williams, Shomir Ghosh, William R. Roush
-
Patent number: 12173002Abstract: Compounds that inhibit Protein Arginine N-Methyl Transferase 5(PRMT5) activity, as well as method for their preparation and use are provided. Specifically, compounds of Formula (I) and pharmaceutically acceptable salts, hydrates and solvates, as well as method for their preparation and use are provided.Type: GrantFiled: February 9, 2024Date of Patent: December 24, 2024Assignee: SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITEDInventors: Bing Yao, Xiaohui Gu
-
Patent number: 12152030Abstract: Provided is a polycyclic compound inhibiting MNK1 and MNK2. Specifically, provided is a compound represented by formula (I), or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein the definition of each group is as described in the description. These compounds can be used for preparing pharmaceutical compositions for the treatment of diseases or disorders related to MNK activity or expression level.Type: GrantFiled: December 4, 2019Date of Patent: November 26, 2024Assignee: NOVOSTAR PHARMACEUTICALS, LTD.Inventor: Bing Li
-
Patent number: 12139505Abstract: Lanthionine ketimine phosphonate (LK-P), lanthionine ketimine ester phosphonate (LKE-P), other lanthionine ketimine, lanthionine ketimine phosphonate, and lanthionine ketimine ester derivatives, methods of making and using the same, and methods of treatments are described.Type: GrantFiled: January 4, 2021Date of Patent: November 12, 2024Assignees: The University of Toledo, Washington State UniversityInventors: Kenneth Hensley, Travis Denton
-
Patent number: 12133852Abstract: The present invention relates to novel ACSS2 inhibitors having activity as anti-cancer therapy, treatment of alcoholism, and viral infection (e.g., CMV), composition and methods of preparation thereof, and uses thereof for treating viral infection, alcoholism, alcoholic steatohepatitis (ASH), non-alcoholic steatohepatitis (NASH), obesity/weight gain, anxiety, depression, post-traumatic stress disorder, inflammatory/autoimmune conditions and cancer, including metastatic cancer, advanced cancer, and drug resistant cancer of various types.Type: GrantFiled: November 4, 2020Date of Patent: November 5, 2024Assignee: EpiVario, Inc.Inventors: Philippe Nakache, Omri Erez, Simone Botti, Andreas Goutopoulos
-
Patent number: 12129242Abstract: The present invention provides novel substituted benzimidazole derivatives used as DAAO inhibitors and for treatment and/or prevention of neurological disorders.Type: GrantFiled: March 30, 2022Date of Patent: October 29, 2024Assignees: NATIONAL TAIWAN UNIVERSITY, NATIONAL YANG MING CHIAO TUNG UNIVERSITY, NATIONAL HEALTH RESEARCH INSTITUTESInventors: Yufeng Jane Tseng, Yu-Li Liu, Chung-Ming Sun, Wen-Sung Lai, Chih-Min Liu, Hai-Gwo Hwu
-
Patent number: 12122791Abstract: The present invention relates to a process for the preparation of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives useful as pharmaceutically active compounds.Type: GrantFiled: June 16, 2022Date of Patent: October 22, 2024Assignee: Hoffmann-La Roche Inc.Inventors: Jean-Michel Adam, Serena Maria Fantasia, Daniel Vincent Fishlock, Fabienne Hoffmann-Emery, Gerard Moine, Christophe Pfleger, Christian Moessner